TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06231225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive Spirometer respiratory training
Description: The incentive spirometer is a handheld mechanical breathing device that uses a one-way valve to prevent exhalation. It consists of a corrugated tube and a nozzle connected to three consecutive plastic chambers, each containing a ball. The external chambers are marked with the minimum flow required to raise the ball internally. The ball rises when the patient performs slow, deep breathing through the nozzle. If the patient breathes too quickly, the balls in the chambers rise to the top, and if breathing is too slow, the balls fall to the bottom. The number of increasing balls measures the volume of inhaled air. When all three balls reach the top of the chambers, the patient's flow rate can reach 1200 ml/s. After the patient has maximized their inhalation, they are asked to hold the balls in the same position for more than 3 sec.
Study: NCT05928533

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clean and boost enamel cleanser of vista apex , RE GEN universal adhesive from vista apex , RE GEN Bio active flowable composite form vista apex
Description: the clean and boost use to clean the tooth surface after cavity preparation without causing severe form of hypersensitivity then the RE GEN universal adhesive is applied by using a brush and cured with the RE GEN flowable composite for 20 seconds. Curing both together increase the bioactivity of the material.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clean and boost enamel cleanser of vista apex , RE GEN universal adhesive from vista apex , RE GEN Bio active flowable composite form vista apex
Description: the clean and boost use to clean the tooth surface after cavity preparation without causing severe form of hypersensitivity then the RE GEN universal adhesive is applied by using a brush and cured with the RE GEN flowable composite for 20 seconds. Curing both together increase the bioactivity of the material.
Study: NCT06271837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab by intravenous infusion
Study: NCT06232408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-1664
Description: RP-1664 will be supplied as immediate-release solid dosage form for oral self-administration.
Study: NCT06365580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kylo-0603 capsule
Description: Administrated orally.
Study: NCT05384327

Intervention type: OTHER
Group type: OTHER
Intervention: Interview
Description: Interviews consist of semi-structured interviews focused on the theoretical knowledge a physician should possess before placing chest tube insertions.

Intervention type: OTHER
Group type: OTHER
Intervention: Multiple Choice Question (MCQ) Test
Description: The test contains multiple choice questions based on these interviews. Participants will complete this test.~Validity evidence will be collected based on the results of this test.

Intervention type: OTHER
Group type: OTHER
Intervention: Multiple Choice Question (MCQ) Test
Description: The test contains multiple choice questions based on these interviews. Participants will complete this test.~Validity evidence will be collected based on the results of this test.

Intervention type: OTHER
Group type: OTHER
Intervention: Multiple Choice Question (MCQ) Test
Description: The test contains multiple choice questions based on these interviews. Participants will complete this test.~Validity evidence will be collected based on the results of this test.
Study: NCT05178043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240mg to be administered as an intravenous (IV) infusion every 2 weeks (Q2W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT90001
Description: GT90001 7mg/kg to be administered as an intravenous infusion every 2 weeks (Q2W) after Nivolumab infusion.
Study: NCT06355583

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EBX-102
Description: EBX-102 is a white size 0 gastro-resistant hydroxypropyl methylcellulose (HPMC) capsule containing communities of dried, intestinal microorganisms extracted from rigorously screened pooled human stool samples obtained from volunteer accredited donors.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The capsules contain inactive ingredients microcrystalline cellulose and magnesium stearate.
Study: NCT05940688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Health intervention
Description: Health care information delivered via a link in a text message that is then opened in a secure browser.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker
Description: Health care information delivered via CHW.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Health Intervention plus Community Health Worker
Description: Health care information delivered via DHI plus CHW
Study: NCT03648398

Intervention type: OTHER
Group type: OTHER
Intervention: EDUMICILOR
Description: Patients will participate in the online therapeutic education program for about 6 months
Study: NCT06317363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Base Line + ACEPELLA
Description: Group A (baseline treatment + acapella) consisting of 15 participants will receive (baseline treatment aerosol therapy, ACBT, Mobilization, breathing with arm elevation with addition to using Acapella). The primary and secondary outcome measures will be assessed at baseline post-op day 1, and after 1 week of surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Base Line + Manual Chest Physiotherapy
Description: The group B consisting of 15 participants will receive base line treatment. aerosol therapy, ACBT, Mobilization, breathing with arm elevation with addition chest physiotherapy percussing for 20 minute. The s primary and secondary outcome measures will be assessed at baseline post-op day 1, and after 1 week of surgery.
Study: NCT06018246

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Malnutrition five-step treatment model + conventional nutritional intervention
Description: 1. Before operation：Same as arm description.~2. After operation:Same as control group.~3. Out-of-hospital: Same as before operation.~4. Strengthening Health Education and psychological intervention:Dietitians need to strengthen health education and communicate with patients during the implementation of nutrition intervention.For patients who actively cooperate with treatment, dietitians can give encouragement.~5. Exercise Instruction:After the operation, according to the tolerance, the dietitian can instruct the patient to take a certain time walking every day, gradually increase the patient's muscle endurance and improve the body resistance.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional nutritional intervention
Description: Routine nutrition support in department.Nutritionists will give patients routine parenteral nutrition support via peripheral or central vein 0-48 hours after surgery and then start enteral nutrition support 48-72 hours after surgery.Patients were initially given half of their enteral nutrition and the rest was supplemented with parenteral nutrition.After adaptation, the patient stopped parenteral nutrition and all nutrition came from enteral nutrition.After the patient's gastrointestinal function gradually recovered, the enteral nutrition could gradually decrease.At this time, nutritionists can let the patient eat some light liquid food, but pay attention to eating a small amount of multiple times.After adaptation, patients can gradually transition from liquid diet to semi-liquid diet.We will educate patients and their families about diet and encourage them to eat more high-quality protein-rich foods.
Study: NCT06112184

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SK-M11/3A1 Digital health program
Description: Digital Health program with participants using an autoinjector delivered via the Sidekick mobile application (app)
Study: NCT06563453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation
Description: Transcranial Alternating Current Stimulation (tACS) is a tool that administers a weak alternating current (in the range of 0.1 to 4 mA), most often with a sinusoidal waveform, between electrodes placed over target areas. This can entrain the subjacent neuronal networks favouring the firing at specific frequencies of interest, in certain cases, with effects outlasting the stimulation duration up to 70 min.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation
Description: Transcranial Alternating Current Stimulation (tACS) is a tool that administers a weak alternating current (in the range of 0.1 to 4 mA), most often with a sinusoidal waveform, between electrodes placed over target areas. This can entrain the subjacent neuronal networks favouring the firing at specific frequencies of interest, in certain cases, with effects outlasting the stimulation duration up to 70 min.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial alternating current stimulation
Description: Transcranial Alternating Current Stimulation (tACS) is a tool that administers a weak alternating current (in the range of 0.1 to 4 mA), most often with a sinusoidal waveform, between electrodes placed over target areas. This can entrain the subjacent neuronal networks favouring the firing at specific frequencies of interest, in certain cases, with effects outlasting the stimulation duration up to 70 min.
Study: NCT06323681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon α-2b based treatment group
Description: Peginterferon α-2b injection, 180mcg, s.c, once a week, for 48 weeks. If the baseline HBV DNA is higher than the minimum detection limit (using high-sensitivity kit), combined with nucleos(t)ide analogs (NAs) is recommended.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAs monotherapy group
Description: First-line NAs (e.g. Entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), tenofovir amibufenamide (TMF)), one tablet a day, take orally, for 48 weeks.
Study: NCT06472375

Intervention type: DIAGNOSTIC_TEST
Intervention: holter
Description: ambulant heart rate monitor (holter) for 24 hour.

Intervention type: DIAGNOSTIC_TEST
Intervention: holter
Description: ambulant heart rate monitor (holter) for 24 hour.
Study: NCT06542783

Intervention type: BEHAVIORAL
Intervention: referring to the results of AI model output
Description: determining the ANA pattern type with or without referring to the results of AI model output.

Intervention type: BEHAVIORAL
Intervention: referring to the results of AI model output
Description: determining the ANA pattern type with or without referring to the results of AI model output.
Study: NCT05218031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: A 90-120 minute 5-week group intervention for unaccompanied minors. Each week there will be a different focus. Week 1: Grounding, Week 2: Unhooking, Week 3: Values, Week 4: Self-compassion, Week 5: Making room for unwanted thoughts and feelings.
Study: NCT06420401

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: araboxylan
Description: During the study period, subjects are instructed to take one pocket of arabosylan per day during the first week, followed by two pockets of araboxylan per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: inulin
Description: During the study period, subjects are instructed to take one pocket of inulin per day during the first week, followed by two pockets of inulin per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: inulin and araboxylan
Description: During the study period, subjects are instructed to take one pocket of inulin and araboxylan per day during the first week, followed by two pockets of inulin and araboxylan per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: During the study period, subjects are instructed to take one pocket of placebo control per day during the first week, followed by two pockets of placebo control per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
Study: NCT06540313

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block
Description: Stellate ganglion block refers to the injection of local anesthetic drugs into tissues around and near SG to regulate the tension of the sympathetic nervous system, inhibit the outflow of the sympathetic nerve in the innervation area of the stellate ganglion to the ipsilateral head, neck, chest and upper limb, and finally achieve the role of regulating the autonomic nervous system, circulatory system, endocrine system and immune system of the human body to maintain dynamic balance. It is used to treat a variety of pain and non-pain diseases.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block
Description: Stellate ganglion block refers to the injection of local anesthetic drugs into tissues around and near SG to regulate the tension of the sympathetic nervous system, inhibit the outflow of the sympathetic nerve in the innervation area of the stellate ganglion to the ipsilateral head, neck, chest and upper limb, and finally achieve the role of regulating the autonomic nervous system, circulatory system, endocrine system and immune system of the human body to maintain dynamic balance. It is used to treat a variety of pain and non-pain diseases.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block
Description: Stellate ganglion block refers to the injection of local anesthetic drugs into tissues around and near SG to regulate the tension of the sympathetic nervous system, inhibit the outflow of the sympathetic nerve in the innervation area of the stellate ganglion to the ipsilateral head, neck, chest and upper limb, and finally achieve the role of regulating the autonomic nervous system, circulatory system, endocrine system and immune system of the human body to maintain dynamic balance. It is used to treat a variety of pain and non-pain diseases.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block
Description: Stellate ganglion block refers to the injection of local anesthetic drugs into tissues around and near SG to regulate the tension of the sympathetic nervous system, inhibit the outflow of the sympathetic nerve in the innervation area of the stellate ganglion to the ipsilateral head, neck, chest and upper limb, and finally achieve the role of regulating the autonomic nervous system, circulatory system, endocrine system and immune system of the human body to maintain dynamic balance. It is used to treat a variety of pain and non-pain diseases.
Study: NCT05734976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: This is the group that receives real electroacupuncture, applied to selected acupuncture points both on the arms and legs, and on the scalp. All procedures were carried out with disposable needles measuring 0.25 mm in diameter (32-gauge) and 44 mm in length.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: electroacupuncture
Description: This is the group that receives real electroacupuncture, applied to selected acupuncture points both on the arms and legs, and on the scalp. All procedures were carried out with disposable needles measuring 0.25 mm in diameter (32-gauge) and 44 mm in length.
Study: NCT06461676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ventrix Bio Extracellular Matrix
Description: VentriGel will be administered by injection into the right ventricle of the heart in the following defined doses per injection. There will be a total of 8 injections. The proposed dose of up to 0.6 mL is administered as up to 8 sequential injections of 4 injections of 0.1 mL each and 4 injections of 0.05 mL each.
Study: NCT05155020

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK120
Description: AK120 regimen 1-subcutaneous injection every two weeks up to week 24, and follow up to week 32.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK120
Description: AK120 regimen 2(first dose doubling)-subcutaneous injection and then every two weeks up to week 24, and follow up to week 32.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK120
Description: AK120 regimen 3(first dose doubling)-subcutaneous injection and then every two weeks up to week 24, and follow up to week 32.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection every two weeks up to week 24, and follow up to week 32.
Study: NCT06099041

Intervention type: DEVICE
Group type: OTHER
Intervention: Nd-YAG Laser for iris depigmentation
Description: Nd-YAG Laser for iris depigmentation
Study: NCT06514209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisatracurium
Description: The initial bolus dose of cisatracurium injection is 0.05-0.1mg/kg, followed by a continuous infusion of 1ug/kg/min of cisatracurium, with data on vital signs, respiratory mechanics, TOF response, etc. recorded after a 15-minute wait. The maintenance infusion dose of cisatracurium is then gradually increased in a gradient of 0.5ug/kg/min, with data collection after a 15-minute wait after each increase. If the patient\&#39;s spontaneous breathing completely disappears, the infusion dose of cisatracurium will no longer be increased, and the titration will end.
Study: NCT06515093

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SanoGraft
Description: single layer amnion amnion-derived allograft

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PelloGraft
Description: dual layer amnion/chorion-derived allograft
Study: NCT05335473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin and Tucidinostat
Description: phase 1b： 3+3 trial design will be used for Tucidinostat dose escalation cohorts phase 2: Eribulin+Tucidinostat
Study: NCT05226468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEI-01
Description: Part1:~Single dose period: Intravenous single dose of NEI-01 with 4 ascending dose levels.~Multiple dose period: Intravenous weekly dose of NEI-01 for 9 weeks with 4 ascending dose levels.~Part2:~Intravenous weekly dose of NEI-01 at the recommended dose obtained from Part 1
Study: NCT05273398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nasal diazepam
Description: Nasal administration of diazepam
Study: NCT06365580

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administrated orally.
Study: NCT05848739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST316
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST316
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST316
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST316
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST316
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI regimen & bevacizumab
Description: FOLFIRI: Days 1 and 15 of each 28-day cycle:~* irinotecan 180 mg/m2 IV over 90 minutes concurrently with~* leucovorin 400 mg/m2 IV over 2 hours, and then~* 5-FU bolus 400mg/m2 (up to 15 min infusion)~* 5-FU 2400 mg/m2 IV over 46 hours~* bevacizumab should be administered as 5mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: 5 mg once a day for the first 21 days of a 28-day cycle
Study: NCT06082531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate injection
Description: The control group was injected into the joint cavity with sodium hyaluronate injection..

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate injection
Description: The control group was injected into the joint cavity with sodium hyaluronate injection..
Study: NCT05140863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149 20mg BID
Description: HSK16149 20mg, orally twice a day, treatment period; 12-weeks fixed dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149 40mg BID
Description: HSK16149 40mg, orally twice a day, treatment period; 12-weeks fixed dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo BID
Description: Placebo, orally twice a day, treatment period; 12-weeks fixed dose
Study: NCT06136494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioural therapy
Description: Psychoeducation aims at teaching patients about chest pain and anxiety and their impact on daily life. Mindfulness is used to raise awareness of what is going on in the body and emotions and to learn how to relate to chest pain. Physical activity consists of psychoeducation and recommendations regarding physical activity with the goal to get patients to learn that their heart tolerates physical activity and to reduce cardiac anxiety and avoidance of physical activity. Avoidance/exposure is to teach patients how avoidance and safety behaviours can maintain/exacerbate chest pain and negatively impact daily life. Acceptance is about learning to accept having the chest pain without letting it take over one's life. The participants will have weekly assignments with weekly feedback and advice. Reminders and encouraging messages will be sent to motivate participants to complete the intervention. The treatment will be carried out through our own web platform.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention control
Description: General support via weekly email contact to check how participants are feeling and how they are dealing with their situation. iCBT will be offered after 3 months.
Study: NCT05848739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonsurf & bevacizumab
Description: Lonsurf 35 mg/m2 twice daily on days 1-5 and days 8-12 every 28 day bevacizumab 5 mg/kg on days 1 and 15. ST316